Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  ganetespib
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-21 of 21 for your search:
Start Over
Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 9090-08, NCT01348126
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 9090-06, NCT01031225
A Study Evaluating STA-9090 in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 9090-05, NCT01039519
Clinical and Translational Study of STA-9090
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 10-029, NCT01111838
STA-9090 in Previously Treated Patients With Advanced Esophagogastric Cancer
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 09-422, NCT01167114
Study of Hsp90 Inhibitor, STA-9090 for Relapsed or Refractory Small Cell Lung Cancer
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 10-048, NCT01173523
STA-9090(Ganetespib) in Metastatic Ocular Melanoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 10-137, NCT01200238
Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 2010-070, NCI-2010-02328, NCT01270880
Open-label Study of STA-9090 for Patients With Metastatic Breast Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 10-145, NCT01273896
STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 11-039, NCT01551693
A Study of Ganetespib in Subjects With ALK-Positive Non-Small-Cell Lung Cancer (NSCLC)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 9090-09, NCT01562015
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 9090-11, NCT01677455
Study of STA-9090, Administered Once-Weekly in Patients With Solid Tumors
Phase: Phase I
Type: Treatment
Status: Completed
Age: 25 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 9090-02, NCT00687934
Study of STA-9090, Administered Twice-Weekly in Patients With Solid Tumors
Phase: Phase I
Type: Treatment
Status: Closed
Age: 25 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 9090-01, NCT00688116
STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 9090-03, NCT00858572
A Phase 1 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous Leukemia
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 9090-04, NCT00964873
A Dose Escalation Study of STA-9090 and Docetaxel in Patients With Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 9090-07, NCT01183364
A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: IRB00049962, WCI2005-11/MMRC037, NCT01485835
Phase I Trial of Ganetespib, Capecitabine, and Radiation in Rectal Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: IRB00054181, STA 9090, NCT01554969
Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 12-015, NCT01579994
STA-9090 in Patients With Advanced Hepatocellular Cancer
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 10-072, NCT01665937
Start Over